Thiamine: Why Alcohol Use Disorder Demands High-Dose B1

← Back to articles

Thiamine (vitamin B1) is a cofactor for three enzymes critical to glucose metabolism: pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase. Without enough thiamine, cells can't fully oxidise carbohydrate, and the brain — which runs almost entirely on glucose — is hit first. Frank deficiency is uncommon in the general population but common enough in alcohol use disorder, after bariatric surgery, in long-standing hyperemesis, and during refeeding to be a recognised medical priority.

Wernicke's and Korsakoff syndromes

Acute thiamine deficiency can cause Wernicke's encephalopathy, classically characterised by confusion, gait ataxia, and eye-movement abnormalities (ophthalmoplegia or nystagmus); untreated, it can progress to the largely irreversible amnestic Korsakoff syndrome. UK Royal College of Physicians and NICE guidance recommend giving parenteral thiamine (typical regimen: Pabrinex IV, equivalent to ~500 mg thiamine three times daily for 2–3 days, then maintenance) to anyone with suspected Wernicke's and to high-risk decompensating drinkers, because oral absorption is too slow and too low to rescue the acute presentation. A Cochrane review of randomised data on thiamine for Wernicke-Korsakoff in people with alcohol use disorder concluded that the available trial evidence is insufficient to dictate optimal dose, frequency, route, or duration — current dosing is largely consensus-based, but the case for early high-dose parenteral treatment is uncontested clinically (Day 2013; PMID 23818100; DOI 10.1002/14651858.CD004033.pub3).

Why oral B1 often disappoints

Standard thiamine mononitrate and thiamine HCl are absorbed via a saturable, carrier-mediated process in the small intestine; absorption flattens at around 4–5 mg per dose, and most of an additional load is excreted unchanged. Fat-soluble derivatives — benfotiamine, sulbutiamine, fursultiamine, and TTFD — cross the gut by passive diffusion and produce substantially higher blood and tissue thiamine levels than equivalent oral thiamine HCl, although the size of that gap depends on the specific derivative and tissue.

Diabetic and alcoholic polyneuropathy

The BENDIP randomised, double-blind, placebo-controlled trial randomised 165 patients with symmetrical distal diabetic polyneuropathy to benfotiamine 600 mg/day, 300 mg/day, or placebo. After 6 weeks, the Neuropathy Symptom Score improved more with benfotiamine than placebo (per-protocol p=0.033), with the larger effect at the 600 mg/day dose; the symptom labelled "pain" responded best (Stracke 2008; PMID 18473286; DOI 10.1055/s-2008-1065351). Mechanistically, benfotiamine activates transketolase and is thought to reduce flux through the polyol, hexosamine, and advanced-glycation pathways implicated in diabetic complications.

Beyond deficiency

Loop diuretics (furosemide, bumetanide) increase urinary thiamine loss and low thiamine status has been documented in a meaningful fraction of heart failure patients; small trials of supplementation have shown improvements in surrogate measures, but no large outcome trial has demonstrated mortality or hospitalisation benefit. The signal is enough to make routine thiamine sufficiency reasonable in this population, not to justify aggressive megadoses.

Safety and dosing

Thiamine is water-soluble and has no established tolerable upper intake level — excess is excreted in urine. For at-risk groups (chronic heavy alcohol use, long-term loop diuretics, post-bariatric, Crohn's, hyperemesis), 50–100 mg/day oral thiamine HCl is a typical maintenance dose. Benfotiamine 150–300 mg twice daily is the research-backed range for diabetic neuropathy. Sulbutiamine is sold off-label for fatigue in some countries but has much thinner evidence. Suspected Wernicke's remains a parenteral-treatment situation; do not rely on oral supplements.